Beyond conventional care: The therapeutic potential of hemoperfusion in severe COVID-19

Hemoperfusion (HP) is an extracorporeal blood purification modality utilized to remove small- to medium-sized molecules, such as toxins and cytokines, that are difficult to remove by conventional hemodialysis. In clinical practice, HP has been successfully used as a salvage therapy for drug overdose and occasionally in patients with liver failure and sepsis.

To summarize the clinical outcomes of a series of patients with severe coronavirus disease 2019 (COVID-19) who received HP.

Here, we summarize the clinical outcomes of a series of 18 patients with severe COVID-19 who received HP in our institution during the COVID-19 pandemic. A review of the literature was also performed.

HP was well-tolerated, and after an average of three sessions, respiratory and cardiovascular parameters as well as blood inflammatory markers improved in most patients. Ten patients were discharged alive. Our literature search identified a total of 20 studies (873 patients) in which HP was used for COVID-19. Nine studies reported improvements in respiratory parameters, and 13 studies (438 patients in total) reported better survival rates in patients undergoing HP.

HP was well-tolerated in patients with severe COVID-19, and most studies reported improved clinical parameters, including better survival rates, when HP was used in patients with severe COVID-19. Further research, especially prospective studies, is needed to evaluate the utility of HP as an early and supportive therapy for critically ill patients due to infectious diseases, such as those with COVID-19 or severe sepsis.